Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced interim data from the Type A portion of the Phase 1b EQUALISE study that showed promising clinical activity in patients with systemic lupus erythematosus (SLE), and pharmacokinetic and pharmacodynamic data supporting the anti-CD6 mechanism of itolizumab. The data were pres
Click here to view original post